Cargando…

PB2260: CIDOFOVIR FOR THE TREATMENT OF ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): A SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Cacace, F., Caprioli, V., D’amico, M. R., De Simone, G., Muriano, F., Paparo, M., Ricciardi, I., Grimaldi, M., Tambaro, F. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431447/ http://dx.doi.org/10.1097/01.HS9.0000851868.82157.e7

Ejemplares similares

PB2260: FIVE-YEAR SINGLE-CENTER EXPERIENCE IN THE TREATMENT OF ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA WITH ABVD
por: Vukovic, Vojin, et al.
Publicado: (2023)

PB2570: TREATMENT WITH INTRAVENOUS CIDOFOVIR IN HEMORRHAGIC CYSTITIS DUE TO BK VIRUS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: EXPERIENCE IN OUR CENTER.
por: Aizpun, Carola Lucia Diaz, et al.
Publicado: (2023)

PB1815: T(8;16)(P11;P13): A RARE CASE OF ACUTE MYELOID LEUKEMIA
por: Cuccurullo, R., et al.
Publicado: (2022)

PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
por: Ussmann, Jule, et al.
Publicado: (2023)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

PB1760: AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE
por: Giagnuolo, G., et al.
Publicado: (2022)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

PB2418: CLINICAL FEATURES AND PROGNOSIS OF ADENOVIRUS INFECTION AFTER HAPLOIDENTICAL DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, Wei, et al.
Publicado: (2023)

PB2204: HIGH SERUM FERRITIN AT INITIAL DIAGNOSIS IS A PREDICTOR OF BONE MARROW FIBROSIS IN PH NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Leone, Aldo, et al.
Publicado: (2023)

PB2316: SAFETY AND EFFICACY OF AUTOLOGOUS HSCT IN NINE PATIENTS WITH AIDS-RELATED NON-HODGKIN LYMPHOMA
por: Liu, Jun, et al.
Publicado: (2023)

PB2181: DOES SARCOPENIA INFLUENCE THE SUCCESS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Erdogan Yucel, E., et al.
Publicado: (2022)

Use of cidofovir in pediatric patients with adenovirus infection
por: Ganapathi, Lakshmi, et al.
Publicado: (2016)

PB2434: DONOR CELL INDUCING IMMUNE-TOLERANCE IMPROVED ENGRAFTMENT IN TΑΒ+ CELL DEPLETED HSCT IN PATIENTS WITH THALASSEMIA MAJOR
por: Liao, Jianyun, et al.
Publicado: (2023)

Adenovirus Infection in Hematopoietic and Solid Organ Paediatric Transplant Recipients: Treatment, Outcomes, and Use of Cidofovir
por: Grasa, Carlos, et al.
Publicado: (2023)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB2462: IMPACT OF ENGRAFTMENT SYNDROME ON THE DEVELOPMENT OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC/HAPLOIDENTICAL PERIPHERAL BLOOD HSCT IN A SINGLE CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2465: ALLOGENEIC HSCT OUTCOMES IN SIX PATIENTS WITH THERAPY RELATED MYELOID NEOPLASMS WITH A HISTORY OF OVARIAN CANCER TREATED WITH CHEMOTERAPY AND PARP INHIBITORS
por: Maria Edoardo Maraglino, Alessio, et al.
Publicado: (2023)

PB2417: PRESENCE´S IMPACT OF NON-SPECIFIC ANTI-HLA ANTIBODIES ON THE DEVELOPMENT OF PRIMARY GRAFT FAILURE IN PATIENTS UNDERGOING PERIPHERAL BLOOD HAPLOIDENTICAL HSCT, EXPERIENCE AT A CENTER IN MEXICO.
por: Daniel Garza Escobar, Juan, et al.
Publicado: (2023)

PB2199: A REAL WORLD STUDY OF PEG-RHG-CSF ON HEMATOPOIETIC RECOVERY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Xu, J., et al.
Publicado: (2022)

PB2680: THE ACTOR-PARTNER INTERDEPENDENCE MEDIATION EFFECT OF INTIMATE RELATIONSHIP ON DYADIC COPING AND FEAR OF CANCER RECURRENCE IN PATIENTS AND THEIR SPOUSES WITH HEMATOLOGICAL MALIGNANCY AFTER HSCT
por: Zhang, Qiuhui, et al.
Publicado: (2023)

PB2007: FACTORS ASSOCIATED WITH EARLY RELAPSE IN MYELOMA PATIENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Karatas, A., et al.
Publicado: (2022)

PB2174: ON THE ROBUSTNESS OF THE BUCCAL EPITHELIUM FOR ASSESSING RECIPIENT DNA PROFILE IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Risinskaya, N., et al.
Publicado: (2022)

PB2203: AGEING OF LONG-TERM ALLOGENEIC HEMATOPOIETIC CELLS RECIPIENTS COMPARED TO THEIR DONORS
por: Czarnogórski, M., et al.
Publicado: (2022)

Adenovirus pneumonia treated with Cidofovir in an immunocompetent high school senior
por: Yoon, Hee-Young, et al.
Publicado: (2019)

PB2474: CONSTRUCTION OF NURSING SCHEME FOR PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREPARE FOR DISCHARGE
por: Wang, LI, et al.
Publicado: (2023)

PB2187: VIABILITY AND PROLIFERATIVE POTENTIAL OF AUTOGRAFT HEMATOPOIETIC STEM CELLS
por: Balashova, V., et al.
Publicado: (2022)

PB2194: ISCHEMIC STROKE IN PATIENTS WITH THROMBOCYTOPENIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pérez Raya, M., et al.
Publicado: (2022)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

PB2406: EFFECT OF PINK NOISE ON IMPROVING SLEEP QUALITY OF PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Wu, Fangfang, et al.
Publicado: (2023)

PB2191: CENTRAL VENOUS ACCESS AND PERIPHERALLY INSERTED CENTRAL CATHETERS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION: A RETROSPECTIVE COMPARISON OF POSSIBLE COMPLICATION RATES
por: Mele, A., et al.
Publicado: (2022)

PB2355: EFFECTS OF CHRONIC DISEASE LOCUS INTERVENTION MODEL ON QUALITY OF LIFE AND STRESS IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Sun, A., et al.
Publicado: (2022)

1705. Treatment of Disseminated Adenovirus with Cidofovir in a Patient with HIV and ESRD
por: Dieringer, Thomas D, et al.
Publicado: (2020)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2357: THE RELATIONSHIP BETWEEN SYMPTOM CLUSTERS AND QUALITY OF LIFE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING EARLY TRANSPLANT: A LONGITUDINAL STUDY
por: Wu, F., et al.
Publicado: (2022)

PB2183: RELAPSE PREDICTS POOR OUTCOMES IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA POST ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Gavriilaki, E., et al.
Publicado: (2022)

Outcomes of Early Administration of Cidofovir in Non-Immunocompromised Patients with Severe Adenovirus Pneumonia
por: Kim, Se Jin, et al.
Publicado: (2015)

2260. Differences in the Prevalence of Inappropriate Antibiotic Prescribing by Payer Type
por: Ladines-Lim, Joseph B, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0s2elamdtm2brlnq2nts7rhhn9